Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

27.94 +1.88 (+7.21%)
Streaming Delayed Price Updated: 10:48 AM EST, Nov 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
Why Is Protalix BioTherapeutics Stock Falling On Friday?
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy. 
Via Benzinga
Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet
Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS). 
Via Benzinga
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
Biotech stock uniQure just popped nearly 250% in one day, with an analyst calling its trial results "amazing". Wall Street sees significant upside to come. 
Via MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. 
Via Benzinga
uniQure Announces Pricing of Upsized $300 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease... 
Via Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
uniQure Stock Jumps On Positive News, But Risks Remain
uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in... 
Via Benzinga
Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding
After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium... 
Via Chartmill
Topics Artificial Intelligence
Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. 
Via Benzinga
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’
UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026. 
Via Stocktwits
uniQure Announces $200 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall
 
Via Benzinga
What's Going On With UniQure Stock Wednesday?
UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease. 
Via Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
Via Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
A Cure For Huntington's Disease? UniQure Launches More Than 240%.
The company's gene therapy slowed disease progression by 75% over three years. 
Via Investor's Business Daily
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness. 
Via Benzinga
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial
The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale. 
Via Stocktwits
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
From uniQure Inc.
Via GlobeNewswire
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease
uniQure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy. 
Via Benzinga
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
From uniQure Inc.
Via GlobeNewswire
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact. 
Via Benzinga
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight. 
Via Benzinga
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies. 
Via Benzinga
uniQure Narrows Loss in Fiscal Q2
Via The Motley Fool
uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares
uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.